MEGGLE USA Inc. appoints Lewis Jackson as new CEO

 

MEGGLE USA Inc. a global leader in pharmaceutical excipients, announced the appointment of Lewis Jackson as its new Chief Executive Officer. Mr. Jackson has many years of global business leadership experience in the pharmaceutical industry, having lived and held executive positions in the United States.

He will work closely with the Director of MEGGLE’s Business Unit Excipients, Ruth Leinenbach. Mr. Jackson assumed his new duties on 12th June, 2023 and reports to the Managing Director of MEGGLE Ingredients, Marcus Hormuth.

“We are delighted to welcome Lewis Jackson, an insightful and decisive leader with a long track record of success, to MEGGLE USA. Mr. Jackson will bring a wealth of international pharmaceutical industry experience and a broad range of industry relationships. We are confident that Mr. Jackson is very well positioned to further grow the Excipient business for MEGGLE”, commented MEGGLE Business Unit Excipients Director, Ruth Leinenbach.

About MEGGLE
MEGGLE Group GmbH, with its headquarters in the Bavarian city of Wasserburg (Germany), operates as a foundation for various business activities in the dairy industry and whey processing. MEGGLE has a proud history of more than 135 years in the dairy market and has reached a turnover of 1.5 bn EUR last year.

The Business Unit Excipients produces pharmaceutical excipients for direct compression, granulation, capsules, sachets, powder blends and dry powder inhalers. With its broad product portfolio, intelligent innovations, and exceptional product quality, MEGGLE plays a leading role in the global pharmaceutical excipients business. With production facilities in Wasserburg (Germany) and Le Sueur, Minnesota (USA), where the requirements of the North American market are served, MEGGLE is prepared to meet customer expectations worldwide.